Avanos Medical, Inc. (AVNS) Reports In-Line Q1 EPS

Avanos Medical, Inc. (NYSE: AVNS) reported Q1 EPS of $0.16, in-line with the analyst estimate of $0.16. Revenue for the quarter came in at $180 million versus the consensus estimate of $175.22 million.

Full Year 2020 Outlook

Due to the rapidly evolving healthcare environment and continued uncertainties resulting from the impact of COVID-19, the company is withdrawing its previously announced full-year 2020 financial guidance, which was issued on February 25, 2020. At this time, the company cannot fully quantify the extent or duration of the impact of the COVID-19 pandemic on its financial results. However, it will continue to monitor the situation and anticipates providing further updates later in the year.

For earnings history and earnings-related data on Avanos Medical, Inc. (AVNS) click here.

You May Also Be Interested In

• Wex, Inc. (WEX) Tops Q2 EPS by 29c; raises guidance
• First Bancorp (FNLC) Tops Q2 EPS by 85c
• NVE Corp (NVEC) Tops Q1 EPS by 132c